FIVE Prosta Spółka Akcyjna (KRS 0001034354, NIP 8133897275) is a Polish company, headquartered in Rzeszów, Podkarpackie voivodeship. FIVE operates in: Research and experimental development on social sciences and humanities (PKD 72.20.Z). Industry: Research and development. The company has been listed in the National Court Register since May 5, 2023.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - FIVE
Identity
- Name
- FIVE Prosta Spółka Akcyjna
- Legal form
- PROSTA SPÓŁKA AKCYJNA
- Founded
- May 5, 2023
- Registry status as of
- November 21, 2025
- Latest entry
- August 27, 2025
- Founding act
- 01.05.2023 R.
Articles of association history (1)
- May 1, 2023: 01.05.2023 R.
Activities
Main activity
72.20.ZResearch and experimental development on social sciences and humanities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. STANISŁAWA STOJAŁOWSKIEGO, 6, 1, 35-120, RZESZÓW, POLSKA
- Voivodeship
- PODKARPACKIE
- District
- RZESZÓW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - FIVE
Credibility rating
54 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
5
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/3 yrs
Board changes
0
0/3 yrs
PKD changes
0
0/3 yrs
Name changes
0
0/3 yrs
Data from 3 years of registry activity.
Credibility history
Payment reliability score from 2023–2024
Current: D (54/100)
Trend: stable (+0.2 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2023–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - FIVE
Founded
May 5, 2023
3 years in operation
Legal form
PROSTA SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
RZESZÓW
PODKARPACKIE
Primary PKD
72.20.Z
Research and experimental development on social sciences and humani…
Share capital
N/A
Shareholders
N/A
Board
1 person
Filed years
2 years
2023–2024
Registry entries
5
latest: August 27, 2025
Revenue
N/A
2024
Net profit
0 PLN
2024
Assets
10.0 K PLN
2024
Equity
10.0 K PLN
2024
Valuation
8.5 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - FIVE.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
